Skip to content

Study · Other design · 2018

7 results

Allelic variant in the glucagon-like peptide 1 receptor gene associated with greater effect of liraglutide and exenatide on gastric emptying: A pilot pharmacogenetics study.

Chedid V, Vijayvargiya P, Carlson P, Van Malderen K, Acosta A, Zinsmeister A, Camilleri M

Neurogastroenterology and motility28 Feb 2018Cited by 54 (Europe PMC)

PMID29488276 (opens in a new tab)PMCIDPMC6003833 (opens in a new tab)DOI10.1111/nmo.13313 (opens in a new tab)PepBankPUB-29488276
Source linkPubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanOther designMechanism

    In obese adults given liraglutide, carriers of the GLP1R rs6923761 A allele had a numerically greater delay in gastric emptying than GG carriers, but the difference was not significant (P = .11).

    In plain wordsIn obese adults given liraglutide, carriers of one gene variant had a numerically longer stomach-emptying delay than others, but the difference was not statistically significant.

    Peptide
    Liraglutide
    Outcome
    No significant changeGastric emptying T1/2 delay by GLP1R rs6923761 genotype, liraglutide
    Study

    n: not reported in source

    Comparator
    GG genotype
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    3 mg daily · 5 weeksAs given in this study (human).

    Measurements

    Gastric emptying T1/2 delay, AA/AG carriers
    128.9 minutes
    liraglutide
    Gastric emptying T1/2 delay, GG genotype
    61.4 minutes
    liraglutide

    Source sentences

    Summary
    GLP1R rs6923761 minor allele A (AA_AG) carriers who received either exenatide or liraglutide had greater delay in GE T1/2 relative to baseline (117.9 ± 27.5 [SEM] minutes and 128.9 ± 38.32 minutes) compared to GG genotype (95.8 ± 30.4 minutes and 61.4 ± 21.4 minutes, respectively; P = .11).
    1 context sentence
    Summary · context
    We evaluated in obese individuals the associations of genetic variations of GLP1R (rs6923761) and TCF7L2 (rs7903146) on GE T1/2 and weight from two trials that evaluated separately exenatide, 5 μg BID for 30 days, or liraglutide, 3 mg daily for 5 weeks.

Studies that did not test the peptide alone6

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

  1. 02HumanNot a test of Exenatide (exendin-4) aloneObservational studyOther

    In obese recipients of exenatide or liraglutide, GLP1R minor-allele carriers had numerically greater gastric-emptying delay than GG carriers (P = .11).

    In plain wordsIn obese recipients of exenatide or liraglutide, stomach-emptying delay did not differ significantly between the reported GLP1R genotype groups.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeGastric emptying by GLP1R genotype
    Study

    n: not reported in source

    Comparator
    GG genotype
    Outcome group
    Gastrointestinal motility · Gastrointestinal

    Measurements

    Gastric emptying T1/2 delay relative to baseline
    117.9 minutes
    AA_AG carriers receiving exenatide or liraglutide, first value of the pair
    Gastric emptying T1/2 delay relative to baseline
    128.9 minutes
    AA_AG carriers receiving exenatide or liraglutide, second value of the pair
    Gastric emptying T1/2 delay relative to baseline
    95.8 minutes
    GG genotype receiving exenatide or liraglutide, first value of the pair
    Gastric emptying T1/2 delay relative to baseline
    61.4 minutes
    GG genotype receiving exenatide or liraglutide, second value of the pair

    Source sentences

    Summary
    GLP1R rs6923761 minor allele A (AA_AG) carriers who received either exenatide or liraglutide had greater delay in GE T1/2 relative to baseline (117.9 ± 27.5 [SEM] minutes and 128.9 ± 38.32 minutes) compared to GG genotype (95.8 ± 30.4 minutes and 61.4 ± 21.4 minutes, respectively; P = .11).
    1 context sentence
    Summary · context
    We evaluated in obese individuals the associations of genetic variations of GLP1R (rs6923761) and TCF7L2 (rs7903146) on GE T1/2 and weight from two trials that evaluated separately exenatide, 5 μg BID for 30 days

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

  2. 03HumanNot a test of Exenatide (exendin-4) aloneObservational studyOther

    In obese participants from exenatide and liraglutide trials, weight change correlated negatively with gastric-emptying half-time change (P = .004).

    In plain wordsIn obese participants from exenatide and liraglutide trials, weight changes were linked inversely to changes in stomach-emptying time.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseAssociation between weight change and gastric-emptying change
    Study

    n: not reported in source

    Outcome group
    Gastrointestinal motility · Gastrointestinal

    Measurements

    Correlation coefficient (rs), weight change versus GE T1/2 change
    −0.382 coefficient
    obese participants from two trials

    Source sentences

    Summary
    There was a significant correlation between changes in weight and GE T1/2 (rs  = -.382, P = .004).
    1 context sentence
    Summary · context
    We evaluated in obese individuals the associations of genetic variations of GLP1R (rs6923761) and TCF7L2 (rs7903146) on GE T1/2 and weight from two trials that evaluated separately exenatide, 5 μg BID for 30 days, or liraglutide, 3 mg daily for 5 weeks.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

  3. 04HumanNot a test of Exenatide (exendin-4) aloneObservational studyOther

    In obese participants from exenatide and liraglutide trials, no significant correlations with TCF7L2 genotype were reported.

    In plain wordsIn obese participants from exenatide and liraglutide trials, the researchers found no significant links with the reported TCF7L2 gene variant.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeCorrelations with TCF7L2 genotype
    Study

    n: not reported in source

    Outcome group
    Receptor activity and mechanism · Whole body

    Source sentences

    Summary
    There were no significant correlations with TCF7L2 (rs7903146) genotype.
    1 context sentence
    Summary · context
    We evaluated in obese individuals the associations of genetic variations of GLP1R (rs6923761) and TCF7L2 (rs7903146) on GE T1/2 and weight from two trials that evaluated separately exenatide, 5 μg BID for 30 days, or liraglutide, 3 mg daily for 5 weeks.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

  4. 05HumanNot a test of Liraglutide aloneOther designMechanism

    In obese adults given exenatide or liraglutide, change in weight correlated significantly with change in gastric emptying T1/2 (r = -.382).

    In plain wordsIn obese adults given exenatide or liraglutide, weight change was linked to change in how fast the stomach empties.

    Peptide
    Liraglutide
    Outcome
    Not applicableCorrelation between weight change and gastric emptying T1/2
    Study

    n: not reported in source

    Outcome group
    Gastrointestinal protection · Gastrointestinal

    Source sentences

    Summary
    There was a significant correlation between changes in weight and GE T1/2 (rs  = -.382, P = .004).
    1 context sentence
    Summary · context
    We evaluated in obese individuals the associations of genetic variations of GLP1R (rs6923761) and TCF7L2 (rs7903146) on GE T1/2 and weight from two trials that evaluated separately exenatide, 5 μg BID for 30 days, or liraglutide, 3 mg daily for 5 weeks.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  5. 06HumanNot a test of Liraglutide aloneOther designEfficacy outcome

    In obese adults given exenatide or liraglutide, weight loss after 5 weeks did not differ significantly by GLP1R rs6923761 genotype.

    In plain wordsIn obese adults given exenatide or liraglutide, weight loss after 5 weeks did not differ significantly by gene variant.

    Peptide
    Liraglutide
    Outcome
    No significant changeWeight loss by GLP1R rs6923761 genotype after 5 weeks
    Study

    n: not reported in source

    Comparator
    GG genotype
    Outcome group
    Body weight · Metabolic and weight

    Source sentences

    Summary
    There was a non-significant difference in weight loss based on GLP1R rs6923761 genotype after 5 weeks of treatment.
    1 context sentence
    Summary · context
    We evaluated in obese individuals the associations of genetic variations of GLP1R (rs6923761) and TCF7L2 (rs7903146) on GE T1/2 and weight from two trials that evaluated separately exenatide, 5 μg BID for 30 days, or liraglutide, 3 mg daily for 5 weeks.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  6. 07HumanNot a test of Liraglutide aloneOther designMechanism

    In obese adults given exenatide or liraglutide, TCF7L2 rs7903146 genotype showed no significant correlations.

    In plain wordsIn obese adults given exenatide or liraglutide, the TCF7L2 gene variant showed no significant links.

    Peptide
    Liraglutide
    Outcome
    No significant changeAssociation of TCF7L2 rs7903146 genotype with gastric emptying and weight
    Study

    n: not reported in source

    Outcome group
    Gastrointestinal protection · Gastrointestinal

    Source sentences

    Summary
    There were no significant correlations with TCF7L2 (rs7903146) genotype.
    1 context sentence
    Summary · context
    We evaluated in obese individuals the associations of genetic variations of GLP1R (rs6923761) and TCF7L2 (rs7903146) on GE T1/2 and weight from two trials that evaluated separately exenatide, 5 μg BID for 30 days, or liraglutide, 3 mg daily for 5 weeks.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Versions 4 to 8Current

    28 Oct 2026, 02:03 UTC

    The same notice was added 5 times, first on 22 Oct 2026, 02:26 UTC. The status did not change between them.

    Study results updated

  2. Version 3

    21 Oct 2026, 18:59 UTC

    Study data updated · source update from Europe PMC

  3. Version 2

    12 Oct 2026, 12:10 UTC

    Study results updated

  4. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.